| Schedule of information regarding reportable segments |
| | | | | | | | | | | | | | | | | | | | For the Year Ended June 30 | | 2026 | | 2025 | | 2024 | Net sales | | | | | | | | | | Animal Health | | $ | 1,162,219 | | $ | 962,796 | | $ | 706,482 | Mineral Nutrition | | | 282,341 | | | 253,240 | | | 243,663 | Performance Products | | | 73,533 | | | 80,179 | | | 67,534 | Total segments | | $ | 1,518,093 | | $ | 1,296,215 | | $ | 1,017,679 |
| | | | | | | | | | | For the Year Ended June 30 | | | 2026 | | 2025 | | 2024 | Animal Health | | | | | | | | | | | Net sales | | | $ | 1,162,219 | | $ | 962,796 | | $ | 706,482 | Cost of goods sold | | | | 692,528 | | | 607,069 | | | 428,683 | Selling, general and administrative expenses (1) | | | | 213,383 | | | 182,310 | | | 162,009 | Add: Depreciation and amortization | | | | 46,268 | | | 40,475 | | | 30,194 | Add: Acquisition-related cost of goods sold (2) | | | | 1,956 | | | 5,679 | | | 521 | Add: Phibro Forward income growth initiatives implementation costs - cost of goods sold (3) | | | | — | | | 3,798 | | | — | Add: Phibro Forward income growth initiatives implementation costs - SG&A (3) | | | | — | | | 1,771 | | | — | Subtract: Insurance proceeds (4) | | | | (954) | | | (2,880) | | | (899) | Adjusted EBITDA | | | | 303,578 | | | 222,260 | | | 145,606 | Mineral Nutrition | | | | | | | | | | | Net sales | | | | 282,341 | | | 253,240 | | | 243,663 | Cost of goods sold | | | | 255,664 | | | 226,864 | | | 222,363 | Selling, general and administrative expenses (1) | | | | 7,221 | | | 7,642 | | | 7,278 | Add: Depreciation and amortization | | | | 2,214 | | | 2,102 | | | 2,427 | Adjusted EBITDA | | | | 21,670 | | | 20,836 | | | 16,449 | Performance Products | | | | | | | | | | | Net sales | | | | 73,533 | | | 80,179 | | | 67,534 | Cost of goods sold | | | | 57,382 | | | 62,364 | | | 53,519 | Selling, general and administrative expenses (1) | | | | 9,056 | | | 8,405 | | | 8,041 | Add: Depreciation and amortization | | | | 966 | | | 1,137 | | | 1,688 | Adjusted EBITDA | | | | 8,061 | | | 10,547 | | | 7,662 | Adjusted EBITDA – Total segments | | | $ | 333,309 | | $ | 253,643 | | $ | 169,717 | Reconciliation of Adjusted EBITDA to income before income taxes: | | | | | | | | | | | Less: | | | | | | | | | | | Interest expense, net | | | | 44,429 | | | 34,602 | | | 18,536 | Depreciation and amortization – Total segments | | | | 49,448 | | | 43,714 | | | 34,309 | Depreciation and amortization – Corporate | | | | 2,066 | | | 1,891 | | | 1,869 | Corporate costs | | | | 78,338 | | | 69,959 | | | 58,480 | Acquisition-related cost of goods sold | | | | 1,956 | | | 5,679 | | | 521 | Acquisition-related transaction costs | | | | 1,305 | | | 13,322 | | | 6,405 | Pension settlement cost | | | | — | | | — | | | 10,674 | Brazil employment taxes | | | | — | | | — | | | 4,202 | Stock-based compensation - named executive officer awards granted in fiscal year 2024 | | | | 717 | | | 717 | | | 475 | Phibro Forward income growth initiatives implementation costs - cost of goods sold (3) | | | | — | | | 3,798 | | | — | Phibro Forward income growth initiatives implementation costs - SG&A (3) | | | | 8,646 | | | 6,978 | | | 366 | Insurance proceeds (4) | | | | (3,563) | | | (2,880) | | | (899) | Foreign currency losses, net | | | | 12,621 | | | 7,870 | | | 23,863 | Income before income taxes | | | $ | 137,346 | | $ | 67,993 | | $ | 10,916 |
| (1) | Selling, general, and administrative expenses primarily include compensation-related expenses for employees not directly involved in the production and sale of inventory, rent expense, research and development costs, marketing expenses, and other general and administrative expenses. |
| (2) | Represents cost of goods sold related to the stepped up value of inventory obtained in acquisitions. |
| (3) | Phibro Forward is a company-wide initiative focused on unlocking additional areas of revenue growth and cost savings. For the year ended June 30, 2026, this includes $8.6 million recorded within selling, general and administrative expenses primarily for consultancy costs related to the initiative. For the year ended June 30, 2025, this included charges of $5.6 million related to the closure of an immaterial business within the Animal Health segment, of which $5.3 million was related to non-cash asset write-offs. $3.8 million of the non-cash asset write-offs was recorded within cost of goods sold and $1.5 million was recorded within selling, general, and administrative expenses. For the year ended June 30, 2025, charges related to Phibro Forward also include $5.2 million for consulting and other costs recorded within selling, general, and administrative expenses. For the year ended June 30, 2024, this included $0.4 million for Corporate consulting costs recorded within selling, general, and administrative expenses. |
| (4) | Represents insurance settlement gains. |
|